|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients.
|
24680815 |
2014 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
However, using four model systems, we showed that long-term silencing of MYCN induces only a small loss of DNA methylation at the RASSF1A promoter in MYCN amplified neuroblastoma cell lines and over-expression of MYCN does not induce any DNA methylation, suggesting that MYCN is not critical for DNA hypermethylation in neuroblastoma.
|
23280764 |
2014 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two members of this gene family, RASSF1A and RASSF5A have been reported as methylated in neuroblastoma.
|
22695170 |
2012 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The RASSF1a(M)-specific quantitative real-time PCR was tested on control bone marrow (BM; n = 50), on 71 NB tumors, and on 159 clinical BM samples at diagnosis and at follow-up of 77 patients.
|
22142825 |
2012 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Epigenetic alterations have been described as well: caspase-8 (CASP8) and RAS-association domain family 1 isoform A (RASSF1A) DNA-methylation are important events for the development and progression of neuroblastoma.
|
21725203 |
2011 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings show that the methylation status of RASSF1A in the serum of patients with neuroblastoma has the potential to become a prognostic predictor of outcome.
|
19165202 |
2009 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Sixty-two NBs (45 primary tumors and 17 NBs at relapse) were studied in terms of the methylation status of 19 genes (p15INK4a, p16INK4a, p14ARF, APC, RB1, RASSF1A, BLU, FHIT, RARbeta, INI1, TIMP3, NF2, MGMT, DAPK, FLIP, ECAD, CASP8, and the receptors DcR1 and DcR2).
|
17570703 |
2008 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The closely related gene family member and functional collaborator RASSF1A is a bona fide tumor suppressor and is frequently involved in neuroblastoma.
|
18452173 |
2008 |
|
Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The RASSF1A (Ras Association Domain Family Protein 1) gene, located at 3p21.3, is highly methylated in multiple primary tumor samples, including neuroblastoma.
|
17899687 |
2007 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
2) Promoter hypermethylation of RASSF1A and CASP8 occurs at a high frequency in neuroblastomas.
|
17064406 |
2006 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the methylation pattern of 14.3.3sigma, RASSF1A and of an intragenic segment of CASP8 was significantly different between MYCN amplified and single copy neuroblastoma suggesting a specific role of epigenetic alterations in aggressive neuroblastoma.
|
16044164 |
2005 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RASSF1A was also methylated in 70% of the primary NB tumors tested, and TSP-1 methylation was detected in 55% of the tumors.
|
15623630 |
2004 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
For the first time, RASSF1A methylation was detected in 54% (7 of 13), 40% (4 of 10), and 9% (1 of 11) of buffy coat samples collected before, during, and after treatment, correspondingly, from pediatric patients with neuroblastoma, thyroid carcinoma, hepatocellular carcinoma, rhabdomyosarcoma, Burkitt's lymphoma, T-cell lymphoma, or acute lymphoblastic leukemia.
|
14871978 |
2004 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
However, there was no significant association between SLIT2 promoter methylation and RASSF1A or CASP8 methylation in NB and RCC.
|
14735202 |
2004 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We recently demonstrated that RASSF1A, a new tumour-suppressor gene located at 3p21.3 is frequently inactivated by promoter region hypermethylation in a variety of human cancers including lung, breast, kidney and neuroblastoma.
|
12584574 |
2003 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
No correlation was found between hypermethylation of RASSF1A and BLU promoter region CpG islands in SCLC or neuroblastoma.
|
12629521 |
2003 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The high frequency of epigenetic inactivation of this gene in a wide range of human sporadic cancers including non-small cell lung cancer (NSCLC) and neuroblastoma suggests that RASSF1A inactivation is important for tumor development.
|
14500366 |
2003 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A high frequency of methylation of RASSF1A is found also in breast cancers, renal cell carcinomas, ovarian, gastric and bladder cancers, and in neuroblastomas.
|
12222680 |
2002 |
|
Neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A promoter region hypermethylation was found in 22% (5/23) of sporadic phaeochromocytomas and in 55% (37/67) of neuroblastomas analysed but RASSF1A mutations were not identified.
|
11709729 |
2001 |